NCT04361279View on ClinicalTrials.gov

A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL

PHASE3CompletedINTERVENTIONAL

Enrollment

421

Participants

Timeline

Start Date

July 25, 2019

Primary Completion Date

May 20, 2022

Study Completion Date

May 20, 2022

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG

SIBP-02

Injection，100mg/10ml

DRUG

Rituximab

Injection，100mg/10ml

Trial Locations (1)

Unknown

The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors

lead

Shanghai Institute Of Biological Products

INDUSTRY

NCT04361279 - A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL | Biotech Hunter | Biotech Hunter